Eisai Resubmits NDA Application for the Anti-epilepsy Drug Rufinamide
Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO Haruo Naito) announced today that its U.S. subsidiary, Eisai Medical Research Inc. (Headquarters: New Jersey, President: Mindell Seidlin), resubmitted the New Drug Application (NDA) for the anti-epilepsy agent rufinamide on November 16, 2005 (US EST time). Eisai Medical Research had withdrawn the original NDA in early November and has supplemented its filing to include copies of some of the data from the original NDA in a more accessible electronic format. Rufinamide has been evaluated as an adjunctive treatment for partial-onset seizures in adult and adolescent patients (12 years and older) and as adjunctive treatment for seizures associated with Lennox-Gastaut Syndrome in children (4 years and older).
Eisai Co., Ltd.
Corporate Communications Department